title: The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
abstract: Patients with skeletal metastases from hormone-refractory prostate cancer have shown variable responses to high-activity therapy with (186)Re-HEDP and peripheral stem cell support. In this paper, we report on the use of a novel technique to compare sequential planar images acquired post-(186)Re-HEDP therapy administration with pretherapy diagnostic (99m)Tc-MDP scans, to evaluate the turnover of the radiopharmaceutical in normal and abnormal bone. It was found that the activity in normal (i.e., disease-free) segments of the spine demonstrates a faster effective decay than that of the metastases, with the latter showing only physical decay. This study showed, for the first time, a detailed correlation in the behavior of the (99m)Tc-MDP and (186)Re-HEDP images, encouraging the possibility of using the pretherapy 99mTc-MDP scan for estimations of absorbed doses to be delivered by prescribed activities of (186)Re-HEDP.
authors.affiliation: Institute of Cancer Research, Royal Marsden Hospital Foundation Trust, Sutton SM2 5PT, UK. David.Binnie@icr.ac.uk
authors.forename: David
authors.initials: D
authors.lastname: Binnie
authors.forename: Antigoni
authors.initials: A
authors.lastname: Divoli
authors.forename: V Ralph
authors.initials: VR
authors.lastname: McCready
authors.forename: David
authors.initials: D
authors.lastname: Dearnaley
authors.forename: Glenn
authors.initials: G
authors.lastname: Flux
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D001842:Bone and Bones / Q000473:pathology; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D016719:Radioimmunodetection / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D012984:Software; D013669:Technetium Tc 99m Medronate / Q000494:pharmacology*; D013997:Time Factors; D014915:Whole-Body Counting
chemical_list: D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate